Top

Published in:

01-01-2014 | Original Paper

Association of vitamin D status and blood pressure response after renal denervation

Authors: Janine Pöss, Felix Mahfoud, Christian Ukena, Murray David Esler, Markus Schlaich, Dagmara Hering, Bodo Cremers, Ulrich Laufs, Michael Böhm

Published in: Clinical Research in Cardiology | Issue 1/2014

Abstract

Background

Vitamin D deficiency is associated with hypertension; however, it is unclear whether vitamin D influences therapeutic blood pressure reduction. Renal sympathetic denervation (RDN) reduces blood pressure in resistant hypertension. We hypothesized that vitamin D might influence blood pressure response to RDN.

Methods

Vitamin D was measured in 101 patients with resistant hypertension undergoing RDN. The associations between vitamin D status and systolic blood pressure (SBP) reduction 6 months after RDN were analyzed.

Results

Mean office SBP at baseline was 171.5 ± 2 mmHg. After RDN, mean office SBP was reduced by 28.4 ± 2.3 mmHg (p = 0.007). 85 patients (84.2 %) had SBP reductions >10 mmHg (responders). Vitamin D concentrations were lower in non-responders as compared to responders (9.9 ± 4.5 vs. 13.7 ± 7.4 ng/ml, p = 0.008). Non-responders (n = 16, 15.8 %), more often had a vitamin D concentration below the median as compared to responders (81 vs. 46 %, p = 0.013). The percentage of patients with normal vitamin D concentrations increased with increasing tertiles of SBP reduction (p for trend = 0.020). In patients with vitamin D concentrations below the median, SBP reduction was lower as compared to patients with a vitamin D concentration above the median (23.5 ± 3.2 vs. 33.7 ± 3.2 mmHg, p = 0.026). Baseline vitamin D concentrations correlated with SBP reduction (r = 0.202, p = 0.043).

Conclusions

In patients with resistant hypertension, low vitamin D concentrations were associated with a decreased SBP response and a higher rate of non-response.

Lee JH, O’Keefe JH, Bell D, Hensrud DD, Holick MF (2008) Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 52(24):1949–1956PubMedCrossRef

Lavie CJ, Lee JH, Milani RV (2011) Vitamin D and cardiovascular disease will it live up to its hype? J Am Coll Cardiol 58(15):1547–1556PubMedCrossRef

Looker AC, Johnson CL, Lacher DA, Pfeiffer CM, Schleicher RL, Sempos CT (2011) Vitamin D status: United States, 2001–2006. NCHS Data Brief 59:1–8PubMed

Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, Felsenfeld A, Levine B, Mehrotra R, Norris K (2007) Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 167(11):1159–1165PubMedCrossRef

Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D’Agostino RB, Wolf M, Vasan RS (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117(4):503–511PubMedCrossRef

Kristal-Boneh E, Froom P, Harari G, Ribak J (1997) Association of calcitriol and blood pressure in normotensive men. Hypertension 30(5):1289–1294PubMedCrossRef

Lind L, Hanni A, Lithell H, Hvarfner A, Sorensen OH, Ljunghall S (1995) Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens 8(9):894–901PubMedCrossRef

DiBona GF, Kopp UC (1997) Neural control of renal function. Physiol Rev 77(1):75–197PubMed

Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376(9756):1903–1909PubMedCrossRef

10.

Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373(9671):1275–1281PubMedCrossRef

11.

Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Böhm M, Krum H (2011) Sympatho-renal axis in chronic disease. Clin Res Cardiol 100(12):1049–1057PubMedCentralPubMedCrossRef

12.

Mahfoud F, Himmel F, Ukena C, Schunkert H, Böhm M, Weil J (2011) Treatment strategies for resistant arterial hypertension. Dtsch Arztebl Int 108(43):725–731PubMedCentralPubMed

13.

Krum H, Sobotka P, Mahfoud F, Böhm M, Esler M, Schlaich M (2011) Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation 123(2):209–215PubMedCrossRef

14.

Ukena C, Mahfoud F, Kindermann I, Barth C, Lenski M, Kindermann M, Brandt MC, Hoppe UC, Krum H, Esler M, Sobotka PA, Böhm M (2011) Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol 58(11):1176–1182PubMedCrossRef

15.

Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M (2011) Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 123(18):1940–1946PubMedCrossRef

16.

Ukena C, Bauer A, Mahfoud F, Schreieck J, Neuberger HR, Eick C, Sobotka PA, Gawaz M, Böhm M (2012) Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol 101(1):63–67PubMedCrossRef

17.

Mahfoud F, Vonend O, Bruck H, Clasen W, Eckert S, Frye B, Haller H, Hausberg M, Hoppe UC, Hoyer J, Hahn K, Keller T, Kramer BK, Kreutz R, Potthoff SA, Reinecke H, Schmieder R, Schwenger V, Kintscher U, Böhm M, Rump LC, Arbeitsgemeinschaft Herz und Niere der Deutschen Gesellschaftfur Kardiologie–Herz–und Kreislaufforschunge VudDGfNVsdDHeVDH (2011) Expert consensus statement on interventional renal sympathetic denervation for hypertension treatment. Dtsch Med Wochenschr 136 (47):2418

18.

Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross AC, Taylor CL, Yaktine AL, Del Valle HB (eds) (2011) Dietary reference intakes for calcium and vitamin D. The National Academies Collection: Reports funded by National Institutes of Health, Washington

19.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289(19):2560–2572PubMedCrossRef

20.

Scragg R, Sowers M, Bell C (2007) Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 20(7):713–719PubMedCrossRef

21.

Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, Curhan GC (2007) Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 49(5):1063–1069PubMedCrossRef

22.

Merke J, Milde P, Lewicka S, Hugel U, Klaus G, Mangelsdorf DJ, Haussler MR, Rauterberg EW, Ritz E (1989) Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest 83(6):1903–1915PubMedCentralPubMedCrossRef

23.

Holick MF (2006) High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 81(3):353–373PubMedCrossRef

24.

Merke J, Hofmann W, Goldschmidt D, Ritz E (1987) Demonstration of 1,25(OH)2 vitamin D3 receptors and actions in vascular smooth muscle cells in vitro. Calcif Tissue Int 41(2):112–114PubMedCrossRef

25.

McGreevy C, Williams D (2011) New insights about vitamin D and cardiovascular disease: a narrative review. Ann Intern Med 155(12):820–826PubMedCrossRef

26.

Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP (2002) 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110(2):229–238PubMedCentralPubMed

27.

Qiao G, Kong J, Uskokovic M, Li YC (2005) Analogs of 1alpha,25-dihydroxyvitamin D(3) as novel inhibitors of renin biosynthesis. J Steroid Biochem Mol Biol 96(1):59–66PubMedCrossRef

28.

Resnick LM, Muller FB, Laragh JH (1986) Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med 105(5):649–654PubMedCrossRef

29.

Carthy EP, Yamashita W, Hsu A, Ooi BS (1989) 1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension 13(6 Pt 2):954–959PubMedCrossRef

30.

Borges AC, Feres T, Vianna LM, Paiva TB (1999) Effect of cholecalciferol treatment on the relaxant responses of spontaneously hypertensive rat arteries to acetylcholine. Hypertension 34(4 Pt 2):897–901PubMedCrossRef

31.

Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD (2008) Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med 25(3):320–325PubMedCrossRef

32.

Dong J, Wong SL, Lau CW, Lee HK, Ng CF, Zhang L, Yao X, Chen ZY, Vanhoutte PM, Huang Y (2012) Calcitriol protects renovascular function in hypertension by down-regulating angiotensin II type 1 receptors and reducing oxidative stress. Eur Heart J 33(23):2980–2990PubMedCrossRef

33.

Intersalt Cooperative Research Group (1988) Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ 297(6644):319–328CrossRef

34.

Woodhouse PR, Khaw KT, Plummer M (1993) Seasonal variation of blood pressure and its relationship to ambient temperature in an elderly population. J Hypertens 11(11):1267–1274PubMedCrossRef

35.

Jorde R, Bonaa KH (2000) Calcium from dairy products, vitamin D intake, and blood pressure: the Tromso Study. Am J Clin Nutr 71(6):1530–1535PubMed

36.

Sowers MR, Wallace RB, Lemke JH (1985) The association of intakes of vitamin D and calcium with blood pressure among women. Am J Clin Nutr 42(1):135–142PubMed

37.

Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C (2001) Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 86(4):1633–1637PubMedCrossRef

38.

Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, Lichtenstein AH, Lau J, Balk EM (2010) Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med 152(5):307–314PubMedCentralPubMedCrossRef

39.

Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD (2012) Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307(7):674–684PubMedCrossRef

40.

Symplicity HTNI (2011) Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 57(5):911–917CrossRef

Title: Association of vitamin D status and blood pressure response after renal denervation
Authors: Janine Pöss
Felix Mahfoud
Christian Ukena
Murray David Esler
Markus Schlaich
Dagmara Hering
Bodo Cremers
Ulrich Laufs
Michael Böhm
Publication date: 01-01-2014
Publisher: Springer Berlin Heidelberg
Published in: Clinical Research in Cardiology / Issue 1/2014
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-013-0621-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Association of vitamin D status and blood pressure response after renal denervation

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease

Coronary vasomotor abnormalities in patients with stable angina after successful stent implantation but without in-stent restenosis

Epidemiology of Chagas disease in Europe: many calculations, little knowledge

Disease distribution and outcome in troponin-positive patients with or without revascularization in a chest pain unit: results of the German CPU-Registry

Closure of a coronary to pulmonary artery fistula by radiofrequency catheter ablation in the pulmonary artery

Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page